Merck will have early-stage opportunities to help startups set up for future success in the pharmaceutical and life sciences fields.

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

Germany's Merck KGaA shares plunged after the company slashed its full-year outlook on the back of uncertainty around tariffs and foreign-exchange headwinds. In European morning trading shares were ...

Roche warned that President Trump's executive order on drug pricing threatens its planned $50 billion investment in the ...

Pharmaceutical company Organon (NYSE:OGN) reported Q1 CY2025 results , but sales fell by 6.7% year on year to $1.51 billion.

The global veterinary antibiotics market is on a strong growth trajectory, anticipated to reach approximately USD 12,820.4 million by 2025 and further expand to an impressive USD 22,559.7 million by ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

Sanofi plans to invest $20 billion in U.S.-based drug R&D and manufacturing over five years, creating jobs and boosting ...

This cash-strapped company is shifting from its roots in cancer drug development to focus on cosmetic treatments.

Leading life science executives, government officials, academic leaders, and investors gather for two day off-the-record ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw158 ...

The global antiviral drugs market is poised for steady expansion, projected to reach a valuation of USD 89.68 billion by 2033, up from USD 61.42 billion in 2023, growing at a Compound Annual Growth ...